ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo, IQVIA Pty Ltd.
Phase
—
Status
Completed
Study type
Observational
Enrollment
140actual
Sites
27
Countries
Austria, Belgium, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-10 | actual | When the study began enrolling |
| Primary completion | 2026-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-17 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bladder Cancer
- Biliary Tract Cancer
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Lung Cancer
- Other Tumors
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Anticipated to be approximately 11 to 17 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed